Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC lifted its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 1.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,510,568 shares of the specialty pharmaceutical company’s stock after purchasing an additional 28,517 shares during the period. Geode Capital Management LLC owned about 2.74% of Supernus Pharmaceuticals worth $54,633,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of SUPN. Smartleaf Asset Management LLC raised its holdings in shares of Supernus Pharmaceuticals by 219.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 870 shares during the last quarter. Mark Sheptoff Financial Planning LLC acquired a new position in Supernus Pharmaceuticals in the 4th quarter valued at $52,000. Newbridge Financial Services Group Inc. purchased a new position in Supernus Pharmaceuticals in the 4th quarter valued at $72,000. Venturi Wealth Management LLC acquired a new stake in Supernus Pharmaceuticals during the 4th quarter worth $92,000. Finally, KBC Group NV grew its holdings in shares of Supernus Pharmaceuticals by 53.1% during the fourth quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock worth $97,000 after buying an additional 929 shares in the last quarter.

Supernus Pharmaceuticals Trading Up 1.9 %

Shares of SUPN stock opened at $31.67 on Monday. Supernus Pharmaceuticals, Inc. has a twelve month low of $25.53 and a twelve month high of $40.28. The stock has a market cap of $1.77 billion, a price-to-earnings ratio of 29.60 and a beta of 0.90. The company’s 50-day moving average price is $33.52 and its 200-day moving average price is $35.07.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on SUPN shares. StockNews.com downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, April 9th. Cantor Fitzgerald restated a “neutral” rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

Insider Buying and Selling at Supernus Pharmaceuticals

In other news, SVP Jonathan Rubin sold 927 shares of the company’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the transaction, the senior vice president now owns 7,853 shares of the company’s stock, valued at $307,444.95. This represents a 10.56 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the transaction, the vice president now owns 10,149 shares of the company’s stock, valued at approximately $402,915.30. This represents a 48.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,104 shares of company stock worth $440,263 in the last ninety days. 9.30% of the stock is owned by insiders.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.